[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100522116":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":42,"responsibleParty":60,"collaborators":36,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":36,"enrollmentInfo":73,"targetDuration":36,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":44,"whyStopped":36,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Asan Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Pulmonary artery catheter monitoring group","EXPERIMENTAL","Within 8 hours of random allocation, a pulmonary artery catheter will be inserted to monitor hemodynamic parameters.",[13],"Device: Pulmonary artery catheter",{"label":15,"type":16,"description":17,"interventionNames":18},"No pulmonary artery catheter monitoring group","ACTIVE_COMPARATOR","After random allocation, a pulmonary artery catheter will not be inserted during cardiogenic shock management.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","Pulmonary artery catheter","Pulmonary artery catheter monitoring or not",[15,9],[26],"Swan-Ganz catheter",[28],{"name":29,"affiliation":5,"role":30},"Min-Seok Kim","STUDY_CHAIR",[32,38],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Min-Seok Kim, PhD","CONTACT","82-2-3010-3948",null,"msk@amc.seoul.kr",{"name":39,"role":34,"phone":40,"phoneExt":36,"email":41},"Ah-Ram Kim, MD","82-2-3010-0111","ahram3256@amc.seoul.kr",[43],{"facility":5,"status":44,"city":45,"state":36,"zip":46,"country":47,"countryCode":36,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Seoul","05505","South Korea",{"type":49,"coordinates":50},"Point",[51,52],126.9784,37.566,{"lat":52,"lon":51},[55,58],{"name":56,"role":34,"phone":57,"phoneExt":36,"email":37},"Min Seok Kim, PhD","02-3010-3948",{"name":39,"role":34,"phone":59,"phoneExt":36,"email":41},"02-3010-0111",{"type":61,"investigatorFullName":29,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":36,"oldOrganization":36},"SPONSOR_INVESTIGATOR","Clinical Associate Professor","100522116","pulmonary-artery-catheterization-and-carvedilol-early-initiation-in-cardiogenic-shock-due-to-hfref-100522116",false,"NCT06078436","Pulmonary Artery Catheterization and Carvedilol Early Initiation in Cardiogenic SHOCK Due to HFrEF","Pulmonary Artery Catheterization and Carvedilol Early Initiation in Cardiogenic SHOCK Caused by Heart Failure With Reduced Ejection Fraction","PACE-SHOCK","Inclusion Criteria:\n\n* Adults age 19 and above ( no age limit for elderly )\n* Patients with cardiogenic shock requiring intensive care monitoring in ICU\n* Patients eligible for oral medication administration\n* Patients who have provided research participation consent through a written informed consent form\n\nExclusion Criteria:\n\n* Unwilling or unable to obtain informed consent by the participant or substitute decision maker\n* Patients with mechanical circulatory support at the time of screening\n* Patients with acute coronary syndrome\n* Patients with severe valvular heart disease requiring emergent percutaneous procedures or surgery\n* Known hypersensitivity to beta-blockers\n* Patients with a history of bronchospasm or asthma\n* Patients with bradycardia or second or third-degree atrioventricular block\n* Patients with sick sinus syndrome, including sinoatrial block\n* Patients with untreated pheochromocytoma\n* Patients currently undergoing de-sensitization therapy\n* Patients who are currently pregnant, postpartum period within 30 days or breast-feeding","ALL","19 Years",{"count":74,"type":75},160,"ESTIMATED","INTERVENTIONAL",[78],"NA","This study aims to compare the impact of hemodynamic monitoring using pulmonary artery catheter (PAC) on survival and inotropic agent reduction in patients with cardiogenic shock caused by heart failure with reduced ejection fraction (HFrEF). The investigators also intend to compare the difference in long-term survival rates among patients who have recovered from cardiogenic shock due to HFrEF, based on the timing of initiation of beta-blocker treatment.",[81,82],"Heart Failure With Reduced Ejection Fraction","Cardiogenic Shock",[84,85,86,22,87],"Cardiogenic shock","Heart failure with reduced ejection fraction (HFrEF)","Hemodynamic monitoring","Carvedilol","2024-01-03",{"date":90,"type":91},"2024-01-05","ACTUAL",{"date":93,"type":75},"2024-01",{"date":95,"type":75},"2028-03",{"name":29,"class":6},1]